RxDoctor Payments DataLook up a doctor →

Teodoro Agtay

Nurse Practitioner · Las Vegas, NVNPI 1407263106

Payments from drug & device makers

$25,408in general payments, 2019–2025

Across 1,308 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novartis$3K
  • Biogen$2K
  • EMD Serono, Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • Amgen$1K
  • plus $13K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)240$4,000
Novartis195$2,753
Biogen65$1,623
EMD Serono, Inc.74$1,588
Neurocrine Biosciences, Inc.50$1,370
Amgen(2 entities)49$1,163
UCB, Inc.49$998
Argenx US, Inc.40$942
Teva Pharmaceuticals USA, Inc.26$808
Genentech USA, Inc.36$790
Pfizer41$593
Bristol Myers Squibb23$530
AstraZeneca(2 entities)17$520
Lilly USA, LLC29$482
ANI Pharmaceuticals, Inc.18$461
TG Therapeutics, Inc.9$417
Corium, LLC23$406
Neurelis, Inc.18$373
Sunovion Pharmaceuticals Inc.30$370
Acadia Pharmaceuticals Inc22$356
Sanofi13$334
Scilex Pharmaceuticals Inc.21$329
Otsuka America Pharmaceutical, Inc.17$315
Lundbeck LLC12$298
Avanir Pharmaceuticals, Inc.17$290
Eisai Inc.15$287
Biohaven Pharmaceuticals, Inc.19$279
Biohaven Pharmaceutical Holding Company Ltd.18$262
Johnson & Johnson(2 entities)11$218
SK Life Science, Inc.7$184
Mallinckrodt Hospital Products Inc.6$158
Grifols USA, LLC7$152
Takeda Pharmaceuticals U.S.A., Inc.7$151
Sumitomo Pharma America, Inc.6$130
Catalyst Pharmaceuticals, Inc.8$122
Aquestive Therapeutics, Inc.6$107
MDD US Operations, LLC5$99
Impel Pharmaceuticals Inc.5$92
Immedica Pharma US, Inc.4$83
Banner Life Sciences, LLC3$79
Jazz Pharmaceuticals Inc.3$76
Sanofi-aventis U.S. LLC4$69
Vanda Pharmaceuticals Inc.3$61
Almatica Pharma LLC3$50
Merz Pharmaceuticals, LLC2$46
Aucta Pharmaceuticals, Inc.5$45
CSL Behring3$43
Biocodex, Inc.1$42
Avion Pharmaceuticals2$42
Kyowa Kirin, Inc.2$41
Revance Therapeutics, Inc.1$39
Supernus Pharmaceuticals, Inc.3$37
Octapharma USA, Inc.2$35
Cycle Pharmaceuticals Inc2$34
Tonix Medicines, Inc.1$31
Axsome Therapeutics, Inc.2$29
Azurity Pharmaceuticals, Inc.1$28
Boston Scientific1$24
Otsuka Pharmaceutical Development & Commercialization, Inc.1$23
Janssen Scientific Affairs, LLC1$23

How this compares

$25,408 in reported general payments places this provider in the 95th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada →

Medicare billing

Part B allowed, 2024
$205,347
Medicare patients
483
Services billed
8,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →